Table 2.
The Clinical and Pathological Characteristics of Different Groups
| Variable | NLR | PLR | LMR | RDW | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <3.4 | ≥3.4 | P value | <157.3 | ≥157.3 | P value | <2.7 | ≥2.7 | P value | <13.1 | ≥13.1 | P value | |
| Age | 0.016* | 0.045* | 0.003* | 0.570 | ||||||||
| <65 | 282 (71.2) | 26 (54.2) | 258 (71.5) | 50 (60.2) | 43 (55.1) | 265 (72.4) | 122 (70.9) | 186 (68.4) | ||||
| ≥65 | 114 (28.8) | 22 (45.8) | 103 (28.5) | 33 (39.8) | 35 (44.9) | 101 (27.6) | 50 (29.1) | 86 (31.6) | ||||
| Male gender | 274 (69.2) | 37 (77.1) | 0.260 | 255 (70.6) | 56 (67.5) | 0.570 | 62 (79.5) | 249 (68.0) | 0.045* | 122 (70.9) | 189 (69.5) | 0.746 |
| Smoking | 117 (29.5) | 21 (43.8) | 0.045* | 114 (31.6) | 24 (28.9) | 0.636 | 33 (42.3) | 105 (28.7) | 0.018* | 46 (26.7) | 92 (33.8) | 0.116 |
| Alcohol | 82 (20.7) | 8 (16.7) | 0.511 | 75 (20.8) | 15 (18.1) | 0.581 | 15 (19.2) | 75 (20.5) | 0.801 | 38 (22.1) | 52 (19.1) | 0.447 |
| Diabetes | 68 (17.2) | 13 (27.1) | 0.093 | 66 (18.3) | 15 (18.1) | 0.964 | 19 (24.4) | 62 (16.9) | 0.123 | 35 (20.3) | 46 (16.9) | 0.361 |
| Hypertension | 180 (45.5) | 27 (56.3) | 0.157 | 166 (46.0) | 41 (49.4) | 0.574 | 44 (56.4) | 163 (44.5) | 0.056 | 77 (44.8) | 130 (47.8) | 0.533 |
| BMI | 0.747 | 0.030* | 0.478 | 0.996 | ||||||||
| <24 | 183 (46.2) | 21 (43.8) | 157 (43.5) | 47 (56.6) | 33 (42.3) | 171 (46.7) | 79 (45.9) | 127 (46.0) | ||||
| ≥24 | 213 (53.8) | 27 (56.3) | 204 (56.5) | 36 (43.4) | 45 (57.7) | 195 (53.3) | 93 (54.1) | 145 (54.0) | ||||
| ECOG | 0.232 | 0.522 | 0.177 | 0.297 | ||||||||
| 0 | 273 (68.9) | 29 (60.4) | 248 (68.7) | 54 (65.1) | 48 (61.5) | 254 (69.4) | 112 (65.1) | 190 (69.9) | ||||
| ≥1 | 123 (31.1) | 19 (39.6) | 113 (31.3) | 29 (34.9) | 30 (38.5) | 112 (30.6) | 60 (34.9) | 82 (30.1) | ||||
| CCI | 0.032* | 0.254 | 0.032* | 0.878 | ||||||||
| 0–1 | 349 (88.1) | 37 (77.1) | 317 (87.8) | 69 (83.1) | 62 (79.5) | 324 (88.5) | 149 (86.6) | 237 (87.1) | ||||
| ≥2 | 47 (11.9) | 11 (22.9) | 44 (12.2) | 14 (16.9) | 16 (20.5) | 42 (11.5) | 23 (13.4) | 35 (12.9) | ||||
| Pathologic tumor size, cm | 0.021* | 0.117 | 0.086 | 0.031* | ||||||||
| <4 | 210 (53.0) | 17 (35.4) | 191 (52.9) | 36 (43.4) | 33 (42.3) | 194 (53.0) | 99 (57.6) | 128 (47.1) | ||||
| ≥4 | 186 (47.0) | 31 (64.6) | 170 (47.1) | 47 (56.6) | 45 (57.7) | 172 (47.0) | 73 (42.4) | 144 (52.9) | ||||
| Pathological tumor stage | 0.095 | 0.576 | 0.049* | 0.493 | ||||||||
| pT1-pT2 | 354 (89.4) | 39 (81.3) | 321 (88.9) | 72 (86.7) | 64 (82.1) | 329 (89.9) | 150 (87.2) | 243 (89.3) | ||||
| pT3-pT4 | 42 (10.6) | 9 (18.8) | 40 (11.1) | 11 (13.3) | 14 (17.9) | 37 (10.1) | 22 (12.8) | 29 (10.7) | ||||
| Pathological node stage | 1.000 | 1.000 | 0.321 | 1.000 | ||||||||
| pN0 | 394 (99.5) | 48 (100) | 359 (99.4) | 83 (100) | 77 (98.7) | 365 (99.7) | 171 (99.4) | 271 (99.6) | ||||
| pN1 | 2 (0.5) | 0 (0) | 2 (0.6) | 0 (0) | 1 (1.3) | 1 (0.3) | 1 (0.6) | 1 (0.4) | ||||
| Fuhrman grade | 0.009* | 0.012* | 0.001* | 0.623 | ||||||||
| 1–2 | 307 (77.5) | 29 (60.4) | 282 (78.1) | 54 (65.1) | 48 (61.5) | 288 (78.7) | 128 (74.4) | 208 (76.5) | ||||
| 3–4 | 89 (22.5) | 19 (39.6) | 79 (21.9) | 29 (34.9) | 30 (38.5) | 78 (21.3) | 44 (25.6) | 64 (23.5) | ||||
| Tumor necrosis | 25 (6.3) | 6 (12.5) | 0.198 | 24 (6.6) | 7 (8.4) | 0.565 | 8 (10.3) | 23 (6.3) | 0.211 | 17 (9.9) | 14 (5.1) | 0.056 |
| UISS risk group | 0.041* | 0.269 | 0.009* | 0.459 | ||||||||
| Low | 191 (48.2) | 19 (39.6) | 175 (48.5) | 35 (42.2) | 32 (41.0) | 178 (48.6) | 75 (43.6) | 135 (49.6) | ||||
| Intermediate | 174 (43.9) | 20 (41.7) | 157 (43.5) | 37 (44.6) | 32 (41.0) | 162 (44.3) | 80 (46.5) | 114 (41.9) | ||||
| High | 31 (7.8) | 9 (18.8) | 29 (8.0) | 11 (13.3) | 14 (17.9) | 26 (7.1) | 17 (9.9) | 23 (8.5) | ||||
| SSIGN risk group | 0.022* | 0.001* | <0.001* | 0.335 | ||||||||
| Low (0–2) | 330 (83.3) | 33 (68.8) | 307 (85.0) | 56 (67.5) | 52 (66.7) | 311 (85.0) | 137 (79.7) | 226 (83.1) | ||||
| Intermediate (3–5) | 59 (14.9) | 12 (25.0) | 48 (13.3) | 23 (27.7) | 21 (26.9) | 50 (13.7) | 29 (16.9) | 42 (15.4) | ||||
| High (≥6) | 7 (1.8) | 3 (6.3) | 6 (1.7) | 4 (4.8) | 5 (6.4) | 5 (1.4) | 6 (3.5) | 4 (1.5) | ||||
Notes: Data presented as n (%). *Statistically significant.
Abbreviations: NLR, Neutrophil-to-Lymphocyte Ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; RDW, red blood cell distribution width; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CCI, Charlson Comorbidity Index; UISS, University of California, Los Angeles, integrated staging system; SSIGN, the stage, size, grade, and necrosis (SSIGN) score.